Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Blagden

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian CancersZhiyuan Hu, Paula Cunnea, Zhe Zhong, et al.
The Lancet. Oncology|July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 14, 2016
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJ C Soria, H K Gan, S P Blagden, et al.
HGG Advances|August 25, 2024
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorderJames Chettle, Raymond J Louie, Olivia Larner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
JCI Insight|May 4, 2021
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Kenta Masuda, Zhiyuan Hu, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian CancersZhiyuan Hu, Paula Cunnea, Zhe Zhong, et al.
The Lancet. Oncology|July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 14, 2016
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJ C Soria, H K Gan, S P Blagden, et al.
HGG Advances|August 25, 2024
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorderJames Chettle, Raymond J Louie, Olivia Larner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
JCI Insight|May 4, 2021
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Kenta Masuda, Zhiyuan Hu, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Pageof 6